Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type

PMID

(37815132)

Authors

Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E

Title

The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.

Journal	Vol	Issue	Date	Pages	Journal Short Title
American journal of hematology	98	12	2023 Dec	E364-E368	Am J Hematol

URL

Abstract Text

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Filter rows:

Showing 1 to 6 of 6 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 exon 14 ins FLT3 N701K	acute myeloid leukemia	predicted - resistant	Azacitidine + Gilteritinib	Case Reports/Case Series	Actionable	In a clinical case study, FLT3 N701K was identified upon progression with Xospata (gilteritinib) and Vidaza (azacitidine) combination treatment in a patient with relapsed acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 37815132).	37815132
FLT3 exon 14 ins FLT3 N701K	acute myeloid leukemia	predicted - resistant	Gilteritinib + Venetoclax	Case Reports/Case Series	Actionable	In a clinical case study, FLT3 N701K was identified upon progression with Xospata (gilteritinib) and Venclexta (venetoclax) combination treatment in a patient with relapsed acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 37815132).	37815132
FLT3 exon 14 ins FLT3 N701K	acute myeloid leukemia	resistant	Midostaurin	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K was resistant to Rydapt (midostaurin) in culture (PMID: 37815132).	37815132
FLT3 exon 14 ins FLT3 N701K	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Patient cell culture	Actionable	In a preclinical study, FF-10101 inhibited viability of a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K in culture (PMID: 37815132).	37815132
FLT3 exon 14 ins FLT3 N701K	acute myeloid leukemia	resistant	Crenolanib	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K was resistant to Crenolanib (CP-868596) in culture (PMID: 37815132).	37815132
FLT3 exon 14 ins FLT3 N701K	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101 treatment inhibited viability of cells expressing a FLT3-ITD mutation and FLT3 N701K in culture (PMID: 37815132).	37815132

Showing 1 to 6 of 6 entries

Filter rows: